2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
6
Phase 3
3
Phase 1
3
Phase 1/2
1
Status
Completed
2
Active not recruiting
1
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Other hematologic neoplasm
2
Lymphoid
1
Conditions
Hematologic Neoplasms
2
Mature B-cell Neoplasms
1
Interventions
Cyclophosphamide
626
pembrolizumab
505
Paclitaxel
456
Gemcitabine
439
Carboplatin
437
Cisplatin
420
Radiotherapy
382
fludarabine
367
Nivolumab
340
Docetaxel
278
Bevacizumab
276
Irinotecan
258
Magnetic Resonance Spectroscopy
245
Fluorouracil
229
Dexamethasone
225
Specimen Handling
223
Capecitabine
218
Rituximab
206
Oxaliplatin
201
Cytarabine
201
Ipilimumab
198
Temozolomide
197
Biopsy
197
fludarabine phosphate
194
Etoposide
181
Lenalidomide
176
Doxorubicin
175
Leucovorin
174
Cetuximab
171
Injections
170
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Phase 1
×
ARQ531
×
Clear all
NCT05673460
2026-05-13
MK-1026-002
Merck Sharp & Dohme LLC
Phase 1
Completed
7 enrolled
15 charts
NCT05347225
2026-04-30
MK-1026-005
Merck Sharp & Dohme LLC
Phase 1
Active not recruiting
12 enrolled
NCT06586671
2024-09-19
MK-1026-007
Merck Sharp & Dohme LLC
Phase 1
Completed
40 enrolled